Search

Your search keyword '"Bolognesi, Dani P."' showing total 287 results
Start Over Author "Bolognesi, Dani P."
287 results on '"Bolognesi, Dani P."'

1. Recombinant polio–rhinovirus immunotherapy for recurrent paediatric high-grade glioma: a phase 1b trial

Author

Thompson, Eric M, Landi, Daniel, Brown, Michael C, Friedman, Henry S, McLendon, Roger, Herndon, James E, II, Buckley, Evan, Bolognesi, Dani P, Lipp, Eric, Schroeder, Kristin, Becher, Oren J, Friedman, Allan H, McKay, Zachary, Walter, Ashley, Threatt, Stevie, Jaggers, Denise, Desjardins, Annick, Gromeier, Matthias, Bigner, Darell D, and Ashley, David M

Published
2023
Full Text
View/download PDF

2. Very low mutation burden is a feature of inflamed recurrent glioblastomas responsive to cancer immunotherapy

Author

Gromeier, Matthias, Brown, Michael C., Zhang, Gao, Lin, Xiang, Chen, Yeqing, Wei, Zhi, Beaubier, Nike, Yan, Hai, He, Yiping, Desjardins, Annick, Herndon, II, James E., Varn, Frederick S., Verhaak, Roel G., Zhao, Junfei, Bolognesi, Dani P., Friedman, Allan H., Friedman, Henry S., McSherry, Frances, Muscat, Andrea M., Lipp, Eric S., Nair, Smita K., Khasraw, Mustafa, Peters, Katherine B., Randazzo, Dina, Sampson, John H., McLendon, Roger E., Bigner, Darell D., and Ashley, David M.

Published
2021
Full Text
View/download PDF

30. Neutralizing antibodies to HIV-1 in seronegative volunteers immunized with recombinant gp120 from the MN strain of HIV-1

Author

Belshe, Robert B., Graham, Barney S., Keefer, Michael C., Gorse, Geoffrey J., Wright, Peter, Dolin, Raphael, Matthews, Thomas, Weinhold, Kent, Bolognesi, Dani P., Sposto, Richard, Stablein, Donald M., Twaddell, Tom, Berman, Phillip W., Gregory, Tim, Izu, Allen E., Walker, Mary Clare, and Fast, Patricia

Subjects
AIDS vaccines -- Evaluation, HIV infection -- Prevention
Abstract

An AIDS vaccine made from the MN strain of recombinant glycoprotein 120 (MN rgp120) appears to be effective at safely inducing antibodies that neutralize the MN, IIIB and SF-2 strains of HIV. All three strains are commonly used in the manufacture of vaccines. Thirty-six HIV-negative subjects received the MN rgp 120 vaccine at varying doses, while 12 received a combination vaccine from both the MN and the IIIB strains of HIV. Two doses were sufficient to induce antibodies to the MN strain in 33 of the 48 subjects. Three doses were sufficient to induce antibodies to the MN strain in 46 of the 48 subjects. Three doses also induced antibodies to the SF-2 strain in 45 of the 48 subjects. Antibodies that neutralized the IIIB strain were induced after three doses in 30 of the 48 subjects. The vaccines appear to be safe and effective, especially when given in multiple doses., Objective.--To evaluate the safety and immunogenicity of the MN strain of recombinant gp120 (MN rgpl 20) as a vaccine prototype to prevent human immunodeficiency virus (HIV). Design.--Double-blind, randomized, placebo-controlled study with subjects vaccinated at 0, 4, 24, and 48 weeks and followed up through 64 weeks. Setting.--The AIDS Vaccine Evaluation Units in St Louis, Mo, Nashville, Tenn, and Rochester, NY, conducted the clinical study. Laboratory studies were conducted at Duke University, Raleigh, NC; data analysis was done by the Data Coordinating and Analysis Center at the EMMES Corporation, Potomac, Md. Participants.--Fifty-seven persons seronegative for HIV, at low risk for acquiring HIV infection, and 18 to 60 years of age. Interventions.--The MN rgp120 vaccine was administered to 12 volunteers each in doses of 1 00 pg, 300 pg, or 600 pg, and 12 volunteers received a combination of 300 pg of MN rgp120 vaccine and 300 pg of vaccine from rgp120 of strain IIIB. Nine volunteers received alum adjuvant alone (control). Main Outcome Measures.--Safety was assessed by monitoring lymphocyte subsets, serum creatinine, and liver enzymes. Immunogenicity was measured by enzyme-linked immunosorbent assay using the immunogen and synthetic peptide corresponding to the variable region 3 domain of gp120. Functional antibody assays included CD4 binding blocking; antibody-dependent, cell-mediated cytotoxicity; and neutralization of homologous and heterologous HIV strains. Results.--No severe adverse reactions occurred. In 33 of 48 volunteer's, two doses of vaccine induced antibodies that neutralized the homologous strain HIV-1/MN. Three doses of vaccine induced antibodies that neutralized MN (in 46 of 48 volunteers), SF-2 (in 45 of 48 volunteers), or IIIB strains of HIV-1 (in 30 of 48 volunteers). Conclusion.--The vaccines were safe and immunogenic. Multiple injections of vaccine broadened and increased the neutralizing antibody response. (JAMA. 1994;272:475-480)

Published
1994

31. Oncolytic polio/rhinovirus recombinant (PVSRIPO) against WHO grade IV malignant glioma (MG): Experience with retreatment of survivors from the phase I trial.

Author

Desjardins, Annick, primary, Gromeier, Matthias, additional, Herndon, James Emmett, additional, Randazzo, Dina, additional, Threatt, Stevie, additional, Lipp, Eric S., additional, Miller, Elizabeth S., additional, Jackman, Jennifer, additional, Bolognesi, Dani P., additional, Friedman, Allan H., additional, Friedman, Henry S., additional, McSherry, Frances, additional, Peters, Katherine B., additional, Johnson, Margaret O, additional, Sampson, John H., additional, Ashley, David M., additional, and Bigner, Darell D., additional

Published
2019
Full Text
View/download PDF

36. HIV Infection in Vaccinated Volunteers.

Author

Belshe, Robert B., Bolognesi, Dani P., Clements, Mary Lou, Corey, Lawrence, Dolin, Raphael, Mestecky, Jiri, Stablein, Donald, and Wright, Peter

Published
1994

37. Comparison of anti-HIV-1 ADCC reactivities in infected humans and chimpanzees

Author

Ferrari, Guido, Place, Cynthia A., Ahearne, Paul M., Nigida, Steven M., Jr., Arthur, Larry O., Bolognesi, Dani P., and Weinhold, Kent J.

Subjects
Antibody-dependent cell cytotoxicity -- Physiological aspects, HIV infection -- Physiological aspects, Animal models in research -- Evaluation, Health
Abstract

HIV-positive chimpanzees appear to produce significantly lower levels of anti-HIV-1 antibody-dependent cellular cytotoxicity (ADCC) antibodies than HIV-positive humans. Antibodies are components of the immune system produced in response to bacteria, viruses or other substances. ADCC antibodies are detected soon after infection in humans and are present throughout the development of AIDS. Blood samples from 10 HIV-positive chimpanzees were analyzed and compared with samples from five HIV-positive humans. ADCC levels were significantly higher in all HIV-positive humans regardless of the stage of their disease. Anti-HIV-1 ADCC antibodies were identified in samples from only three of the chimpanzees. ADCC antibodies were present in chimpanzees only within several months of infection. This finding may help explain the differences in disease progression between chimpanzees and humans.

Published
1994

38. Neutralizing Antibody Responses to Human Immunodeficiency Virus Type 1 in Primary Infection and Long-Term-Nonprogressive Infection

Author

Pilgrim, Alice K., Pantaleo, Giuseppe, Cohen, Oren J., Fink, Lisa M., Zhou, Ji Ying, Zhou, Jin Tao, Bolognesi, Dani P., Fauci, Anthony S., and Montefiori, David C.

Abstract

The role of neutralizing antibodies in human immunodeficiency virus type 1 (HIV-1) infection is poorly understood and was assessed by evaluating responses at different stages of infection. Undiluted sera from long-term nonprogressors (LTNP) had broad neutralizing antibodies against heterologous primary isolates and were more likely to neutralize the contemporaneous autologous isolate than were sera from short-term nonprogressors and progressors. In primary infection, envelopespecific IgG was detected before the initial decline in plasma viremia, but neutralizing antibodies developed more slowly. Here, neutralizing antibodies against strains SF-2 and MN were sometimes the first to be detected, but titers were low for at least 17 weeks from onset of symptoms. Neutralizing antibodies against the early autologous isolate were detected for 4 patients by 5-40 weeks but were undetectable in 2 additional patients for 27-45 weeks. The results indicate that neutralizing antibody responses are slow to develop during primary infection and are uniquely broad in LTNP

Published
2017

41. Overview

Author

Bolognesi, Dani P. and Schild, Geoffrey C.

Published
1990

42. Alterations in antibody-dependent cellular cytotoxicity during the course of HIV-1 infection

Author

Tyler, Douglas S., Stanley, S. David, Nastala, Chet A., Austin, Arthur A., Bartlett, John A., Stine, Kimo C., Lyerly, H. Kim, Bolognesi, Dani P., and Weinhold, Kent J.

Subjects
Immunotherapy -- Research, Cellular immunity -- Physiological aspects, HIV (Viruses) -- Physiological aspects, AIDS (Disease) -- Physiological aspects, Health
Abstract

Cell-mediated cytotoxicity (CMC) specific for human immunodeficiency virus (HIV) is a type of antibody dependent cellular cytotoxicity (ADCC) activity, in which antibodies to HIV bind to immune cells, known as natural killer (NK) cells, enabling them to kill any cell containing HIV antigens. This type of cellular immunity occurs in early stages of the disease, but decreases with the progression of HIV. The factors that contribute to the decline of this activity were examined by studying the various conditions under which antibodies bind to the NK cells. Sera from patients with HIV infection were tested for the presence of antibodies that allow ADCC activity and for the binding of antibody to NK cells. HIV-infected patients without symptoms of AIDS had low levels of antibodies for ADCC, but did not have antibodies that could bind to NK cells. However, patients with AIDS had large amounts of antibodies for ADCC activity, but did not have antibodies that could bind to NK cells. There was also a group of patients who had low levels of CMC, but large amounts of antibodies which could bind to NK cells. This indicates that other factors besides the amount of antibody specific to HIV are involved in the decrease of CMC. Lymphocytes from AIDS patients had lower levels of ADCC and NK activity, compared with normal individuals, even if there was a lot of antibody present so that these cells could be armed. Therefore, in patients who are infected with HIV, there are defects in both the types and levels of antibodies and in the cells themselves. These defects result in the decline of CMC activity. To know what conditions would allow the arming of NK cells is important, since this information could be used to develop a type of immunotherapy for HIV infection or AIDS. (Consumer Summary produced by Reliance Medical Information, Inc.)

Published
1990

43. Progress in vaccine development against SIV and HIV

Author

Bolognesi, Dani P.

Subjects
AIDS vaccines -- Research, HIV (Viruses) -- Research, HIV antibodies -- Research, AIDS (Disease) -- Prevention, Health
Abstract

Recent advancements in the development of a vaccine against the human immunodeficiency virus type-1 (HIV-1) have caused some optimism, when it was felt that the problems were insurmountable. One of the most important of these advances is the development of effective vaccines against the simian immunodeficiency virus (SIV) and equine infectious anemia virus (EIAV), which serve as animal models for HIV. Whole virus, which has been killed, has been used as a vaccine and causes a delayed onset of disease. In some cases, the disease does not develop at all. The delay of the onset of disease occurs even though the virus is still able to cause an infection. This implies that the virus does not have to be completely eliminated and that infection may not have to be stopped for a vaccine to be successful. Using these animal models, the molecules that are responsible for instilling protection and the mechanisms of protection can be studied. Another important advancement toward the development of a vaccine is the understanding of the epitopes, or the particular regions on molecules that provoke an immune response. The main epitope to which an antibody response is made, which neutralizes or inhibits the virus from attaching to cells, has been identified. This epitope is located on the envelope protein of the virus, which forms the outer coat of the virus particle. Studies have shown that when animals are given antibodies to this region along with the virus, the antibodies can protect the animals from developing an infection with HIV. If a peptide containing the epitope is administered to animals, the animals produce large amounts of antibodies which stop the virus from causing an infection. The antibodies also protect against future infections with the virus for a certain period of time. Therefore, recent advancements have been made, which bring scientists closer to the development of a vaccine against AIDS. (Consumer Summary produced by Reliance Medical Information, Inc.)

Published
1990

44. AIDS Vaccines.

Author

Matthews, Thomas J. and Bolognesi, Dani P.

Abstract

Reveals that success of discovering vaccines is far from being assured although several candidates are being tested. States that the devious nature of the virus, the lack of a good animal model for the disease, and the difficulties of clinical trials inhibit the efforts of researchers. (RT)

Published
1988

45. Recurrent Glioblastoma Treated with Recombinant Poliovirus

Author

Desjardins, Annick, primary, Gromeier, Matthias, additional, Herndon, James E., additional, Beaubier, Nike, additional, Bolognesi, Dani P., additional, Friedman, Allan H., additional, Friedman, Henry S., additional, McSherry, Frances, additional, Muscat, Andrea M., additional, Nair, Smita, additional, Peters, Katherine B., additional, Randazzo, Dina, additional, Sampson, John H., additional, Vlahovic, Gordana, additional, Harrison, William T., additional, McLendon, Roger E., additional, Ashley, David, additional, and Bigner, Darell D., additional

Published
2018
Full Text
View/download PDF

46. Determinants of Antibody Response after Recombinant gp160 Boosting in Vaccinia-Naive Volunteers Primed with gp160-Recombinant Vaccinia Virus

Author

National Institute of Allergy and Infectious Diseases AIDS Vaccine Clinical Trials Network, Graham, Barney S., Gorse, Geoffrey J., Schwartz, David H., Keefer, Michael C., McElrath, M. Juliana, Matthews, Thomas J., Wright, Peter F., Belshe, Robert B., Clements, Mary Lou, Dolin, Raphael, Corey, Lawrence, Bolognesi, Dani P., Stablein, Donald M., Esterlitz, Joy R., Hu, Shiu-Lok, and Smith, Gale E.

Published
1994

47. Augmentation of Human Immunodeficiency Virus Type 1 Neutralizing Antibody by Priming with gpl60 Recombinant Vaccinia and Boosting with rgpl60 in Vaccinia-Naive Adults

Author

NIAID AIDS Vaccne Clinical Trails Network, Graham, Barney S., Matthews, Thomas J., Belshe, Robert B., Clements, Mary Lou, Dolin, Raphael, Wright, Peter F., Gorse, Geoffrey J., Schwartz, David H., Keefer, Michael C., Bolognesi, Dani P., Corey, Lawrence, Stablein, Donald M., Esterlitz, Joy R., Hu, Shiu-Lok, Smith, Gale E., Fast, Patricia E., and Koff, Wayne C.

Published
1993

Catalog

Books, media, physical & digital resources
See catalog results